Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dicyclomine (also known as dicycloverine) is an anticholinergic and antispasmodic small molecule drug primarily used to treat symptoms of irritable bowel syndrome (IBS), particularly intestinal spasms and hypermotility. It acts as a muscarinic receptor antagonist—specifically at the M1, M2, and M3 subtypes—blocking acetylcholine at these sites in the gastrointestinal tract. This leads to relaxation of smooth muscle and reduced cramping. Dicyclomine also non-competitively inhibits bradykinin- and histamine-induced spasms in the gut. The drug was first approved for medical use in 1950 and is available both as a generic medication and under several brand names[1][2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dicyclomine.